Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 May 2];9(6):s695. Available from: https://skin.dermsquared.com/skin/article/view/3825